Frost & Sullivan Independent Equity Research

DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.

Company: DNA Biomedical Solutions, Ltd.

Sector: Healthcare

Report type: Q2-2018 Update & 12 Months Since Initiation of Coverage

Published on: 12 September, 2018

View Fullscreen

Download full report

DNA research articles:

12 months since initiation ·
Q2-2018 ·

DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.

Quarterly Update ·

DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.

All articles loaded

No more articles to load

INDEPENDENT EQUITY RESEARCH

Tel: +972(0)9.950.2888
Email: equity.research@frost.com

Contact us

Copyright © 2020 Frost & Sullivan. All Rights Reserved. Privacy Policy.

Accessibility by WAH